Phase Ib Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer

Trial Profile

Phase Ib Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Buparlisib (Primary) ; Bicalutamide; LHRH receptor agonists
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms NCMPC-BKM
  • Most Recent Events

    • 01 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Sep 2017.
    • 01 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Aug 2017.
    • 30 Jan 2017 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top